A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

ABSTRACT: This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

DISEASE(S): Lymphoma, Large B-cell, Diffuse,Marginal Zone Lymphoma,Lung Cancer,Pancreatic Adenocarcinoma,Carcinoma,Hepatic Cancer,Colorectal Cancer,Fallopian Tube Cancer,Indolent B-cell Lymphomas,Liver Neoplasms,Lung Neoplasms,Non-hodgkin Lymphoma,Ovarian Cancer,Bladder Urothelial Carcinoma,Fallopian Tube Neoplasms,Other Solid Tumors,Waldenstrom's Disease,Lymphoplasmacytic Lymphoma,Gastric Cancer,Lymphoma, Mantle-cell,Diffuse Large B-cell Lymphoma (dlbcl),Primary Peritoneal Cancer,Renal Cell Carcinoma,Cholangiocarcinoma,Melanoma,Breast Cancer,Lymphoma,Follicular Lymphoma,Mucosa Associated Lymphoid Tissue,Lymphoma, Follicular,Waldenstrom Macroglobulinemia,Non-small Cell Lung Cancer,Mantle Cell Lymphoma,Esophageal Cancer,Lymphoma, Non-hodgkin,Head And Neck Cancer,Lymphoma, B-cell,Solid Tumors,Small Lymphocytic Leukemia

PROVIDER: 2257952 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR